# Huadao Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huadao-biology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $31M
- Latest round: Series D (Oct 11, 2025)
- Investors on record: 15

## About

Based in Shanghai, China, and established in 2017, Huadao Biology is a cellular immunity therapy technology provider that focuses on R&D of cell therapy drugs and industry chain production technology. The company is a high-tech biomedicine enterprise. Also, it is the only CAR-T cell drug R&D company with independent intellectual property rights in China. The company is building cell drug R&D and transformation production bases in six central cities in China.

In February 2024, the firm closed a series D+ funding. In October 2025, Huadao Biology closed series D+2 funding led by returning investor Boai Nky Medical Holdings Ltd., with participation from new investor Jinghu Fund, and other investors.

The company developed the CAR-T cell products industry chain production system, which includes engineered bacteria fermentation, plasmid purification, virus packaging, virus purification, T cell acquisition, T cell transfection, and freezing. Up to 2021, it has carried out R&D of nearly 30 cases of CD19- CAR-T in the treatment of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Also, it developed the preclinical cytlogy of CAR vectors for other tumors, such as gastric cancer, liver cancer, pancreatic cancer, and glioma.

The company plans to build Huadao Biology Songjiang base phase II project. Also, it will compete HD CD19 CAR-T injection phase II clinical trial.

## Funding rounds

- Series D, Oct 11, 2025 — Boai Nky Medical Holdings Ltd., Jinghu Capital
- Series D, Feb 23, 2024 — Kexing Venture Capital, Boai Nky Medical Holdings Ltd.
- Series D, Nov 16, 2021 — HRVC Capital, HY Energy Group, Jiaxing Industrial Investment Group Co.,Ltd., Huzhou Industrial Investment Development Group Co.,Ltd., Hangzhou perspective investment management partnership (limited partnership)
- Series C, Dec 3, 2020, $31M — Sinowisdom, Chongqing Venture Capital, Yuhui Fund, Houlu Investment
- Angel, Nov 8, 2017 — CCB Private Equity Investment Management, Oceanpine Capital, Baichuan Huida Investment

## Investors

- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Angel
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Angel
- Baichuan Huida Investment (https://capitalatlas.ai/funds/baichuan-huida-investment) — Angel
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series C
- Chongqing Venture Capital (https://capitalatlas.ai/funds/chongqing-venture-capital) — Series C
- Yuhui Fund — Series C
- Houlu Investment — Series C
- HRVC Capital (https://capitalatlas.ai/funds/hrvc-capital) — Series D
- HY Energy Group — Series D
- Jiaxing Industrial Investment Group Co.,Ltd. — Series D
- Huzhou Industrial Investment Development Group Co.,Ltd. — Series D
- Hangzhou perspective investment management partnership (limited partnership) — Series D
- Kexing Venture Capital (https://capitalatlas.ai/funds/kexing-venture-capital) — Series D
- Boai Nky Medical Holdings Ltd. — Series D
- Jinghu Capital (https://capitalatlas.ai/funds/jinghu-capital) — Series D